Aktis Oncology (NASDAQ:AKTS) Upgraded at BMO Capital Markets

Aktis Oncology (NASDAQ:AKTS) was upgraded by analysts at BMO Capital Markets to a “strong-buy” rating in a research report issued to clients and investors on Tuesday, MarketBeat Ratings reports.

A number of other equities research analysts have also issued reports on the company. Wall Street Zen lowered Aktis Oncology from a “hold” rating to a “sell” rating in a research note on Saturday, July 25th. William Blair assumed coverage on Aktis Oncology in a report on Wednesday, April 29th. They issued an “outperform” rating for the company. HC Wainwright increased their price objective on shares of Aktis Oncology from $33.00 to $35.00 and gave the company a “buy” rating in a research report on Tuesday, June 2nd. Weiss Ratings raised shares of Aktis Oncology from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, June 23rd. Finally, JPMorgan Chase & Co. upped their target price on shares of Aktis Oncology from $30.00 to $33.00 and gave the company an “overweight” rating in a research note on Tuesday, July 14th. Two analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $35.00.

Aktis Oncology Trading Up 0.1%

Shares of Aktis Oncology stock opened at $25.02 on Tuesday. Aktis Oncology has a twelve month low of $14.72 and a twelve month high of $34.19. The stock has a market cap of $1.34 billion and a price-to-earnings ratio of -30.51. The company has a fifty day moving average price of $25.35 and a 200 day moving average price of $21.25.

Aktis Oncology (NASDAQ:AKTS) last released its quarterly earnings data on Thursday, August 13th. The technology company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.01). The business had revenue of $3.38 million during the quarter, compared to the consensus estimate of $2.70 million. Analysts forecast that Aktis Oncology will post -1.76 earnings per share for the current year.

Insider Activity

In related news, Director Ken Herrmann sold 4,856 shares of Aktis Oncology stock in a transaction on Monday, July 20th. The shares were sold at an average price of $24.56, for a total value of $119,263.36. Following the completion of the sale, the director owned 3,506 shares in the company, valued at approximately $86,107.36. The trade was a 58.07% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 3.30% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in AKTS. BlackRock Inc. grew its position in shares of Aktis Oncology by 7.9% during the 2nd quarter. BlackRock Inc. now owns 2,278,358 shares of the technology company’s stock valued at $73,431,000 after buying an additional 166,231 shares during the last quarter. Wellington Management Group LLP bought a new position in Aktis Oncology in the second quarter worth about $63,372,000. Jupiter Topco LLC acquired a new position in Aktis Oncology in the second quarter valued at approximately $42,359,000. Alyeska Investment Group L.P. acquired a new position in Aktis Oncology in the second quarter valued at approximately $9,347,000. Finally, Bank of America Corp DE grew its holdings in shares of Aktis Oncology by 4.2% during the second quarter. Bank of America Corp DE now owns 72,835 shares of the technology company’s stock valued at $2,347,000 after purchasing an additional 2,909 shares during the last quarter. 28.84% of the stock is owned by institutional investors and hedge funds.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.